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ABSTRACT 
PET/MRI is an emerging imaging technology that allows for the acquisition of multiple MRI 
parameters simultaneously with PET data.  In this review, we’ll address the technical 
requirements of PET/MRI including protocols and tracers, the potential of integrated localized 
breast PET/MRI exams, and possible applications of whole body PET/MRI in breast cancer 
patients. Currently, PET/MRI can be performed on sequential and integrated PET/MRI scanners 
but, as not all practices can access these dedicated machines, several studies look at PET and 
MRI exams that are performed separately on separate scanners within a short time frame.  This 
practice likely provides similar clinical data, although exact co-localization for iso-voxel analysis, 
currently performed only in research, is not possible.  In PET/MRI, the MRI sequences are 
flexible and can be customized according to the aim of the exam.   The most commonly used 
radiotracer is 18F-FDG, however, tracers that image hypoxia and drug targets such as estrogen 
receptors and HER2 are in development and may increase the utility of PET/MR.  For dedicated 
breast PET/MRI, a potential advantage over standard breast MRI alone may be the 
complimentary sensitivities of MRI for extent of disease within the breast and PET for axillary 
and internal mammary nodal metastases. .  Moreover, layers of multiparametric MRI and PET 
metrics derived from the index lesion are being investigated as predictors of response to 
neoadjuvant therapy.  These data may eventually be able to be quantified and mined in a way 
that furthers radiomics and also precision medicine. Finally, in whole body imaging of breast 
cancer patients, single institution studies have found that PET/MRI detects more metastases 
than PET/CT   at about half the radiation dose, although survival benefit has not been shown. 
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For now, whole body PET/MRI in breast cancer patients may be most relevant for young 
patients who may undergo serial surveillance exams. 
Keywords:  PET/MRI, breast MRI, breast PET/MRI, multi-parametric, response to neoadjuvant 
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INTRODUCTION 
Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) have been 
combined into integrated PET/MR imaging, an imaging tool that acquires both the metabolic 
data of PET and, most often, the high contrast morphological data of MRI as part of a single 
exam.  Advanced MR techniques such as proton MR spectroscopy (MRS) and diffusion weighted 
imaging (DWI) can also be run simultaneously with PET acquisition, broadening potential clinical 
oncologic and research applications.   
MRI and PET imaging are both commonly used in breast cancer.  PET imaging in breast cancer is 
most often used in the form of PET/CT with fluorine-18 fludeoxyglucose (18F-FDG) to assess for 
distant metastatic disease and to look for and monitor recurrent disease (1).  Positron Emission 
Mammography (PEM) is also used in breast imaging, but this system has a higher spatial 
resolution and smaller field of view than whole body PET imaging and is not currently 
integrated with MRI for breast imaging (2).  As such, PEM is not discussed in this review. 
 
Dynamic contrast enhanced (DCE) MRI is both a morphologic and a functional imaging tool that, 
in addition to providing morphologic data, depicts areas of increased blood-flow, an early 
characteristic of breast cancers and an obligate characteristic of biologically relevant breast 
cancers.  DCE MRI is the most sensitive tool for breast cancer screening (3,4) and is also used to 
assess the extent of disease in patients with known breast cancers and to monitor breast 
cancers during and after neo-adjuvant therapy (5).  Preliminary investigtaions of advanced 
perfusion, diffusion, spectroscopy, and sodium imaging MR techniques are underway to further 
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characterize breast cancers.  Eventually, these tools may help to match specific imaging 
characteristics with disease characteristics and behavior (radiomics) and with genetic 
information (radiogenomics).   
Breast MR cannot always differentiate benign from malignant enhancement and cannot 
identify locally advanced disease in morphologically normal lymph nodes.  PET breast imaging 
has demonstrated increased specificity as compared with MR (6, 7) and high sensitivity for 
axillary lymph node metastases (8,9).  Fusing separate PET and MR breast imaging has been 
looked at as a means to preserve the sensitivity of MR, decrease false positive exams, and 
increase axillary nodal metastasis sensitivity (10-13).   This field was limited by the logistic 
limitations of requiring patients to undergo multiple exams and the technical and temporal 
limitations of fusing the two exams.  Now, however, PET and MR imaging can be acquired 
simultaneously and co-registered, allowing radiologists to evaluate not only how the 
combination of exams can improve sensitivity and specificity, but also to put together exams 
with multiple parameters (eg. PET, DCE MRI, DWI MRI, MRS).  With multi-parametric imaging, 
radiologists can assess layers of parameters voxel-by-voxel, and use this information to 
characterize tumor heterogeneity and to search for multi-parametric hints at predicting clinical 
outcomes.    
TECHNICAL 
PET and MR fusion became clinically viable with advances in PET detectors.  Traditional PET 
photomultiplier tubes used in PET/computed tomography (CT) systems are not compatible with 
the high magnetic fields integral to MR imaging, and photomultiplier tubes are too large to fit 
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into an MR gantry.  The development of MRI-compatible solid state PET detectors facilitated 
placing PET and MR scanners in the same space.   Two non-integrated PET/MRI systems scan 
patients sequentially, with patients undergoing PET or PET/CT and MRI separately in the same 
room while the patient’s position is unchanged.  The sequential PET/CT and MRI system allows 
for CT-based attenuation correction.  Although these systems provide improved co-localization 
over completely separate MR and PET exams, they do not allow for dynamic imaging on both 
systems.  Integrated, simultaneous PET/MR imaging depends on solid-state semiconductor PET 
detectors, such as avalanche photodiodes, which are much smaller than conventional PET 
detectors (14) and can be placed inside an MR gantry.   This type of integrated system performs 
both exams at the same time, providing a shorted exam time for patients, and the opportunity 
to visualize dynamic processes with both modalities.  An integrated system, or any system 
without CT, requires MR-based attenuation correction, most commonly achieved through a 
Dixon sequence-based segmentation method (7, 14-16).  MR-based attenuation correction for 
breast and body PET/MRI has been validated (17-24). 
 
Radiotracers 
There are only two FDA approved PET radiotracers used in breast cancer imaging, 18F-FDG and 
Fluorine 18-sodium fluoride (18F-NaF).  18F-FDG images cellular glucose uptake and is highly 
sensitive for breast cancers and for breast cancer metastases in a wide range of organs (23).  
18F-FDG has some limitations including lower sensitivity for lobular breast cancers (25, 26), 
ductal carcinoma in situ (DCIS) (26), and, as the reconstructed spatial resolution of PET is 5-
6mm at full width half maximum (1), for small, sub-centimeter tumors (27).  Conversely, 18F-
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FDG can show increased uptake in benign breast processes including common entities like 
fibrocystic changes, fibroadenomas, and fat necrosis (28, 29).   
 
18F-NaF is a bone specific radioisotope that has been investigated in breast cancer patients (30, 
31).  Piccardo et al demonstrated that in the setting of PET/CT, 18F-NaF had a higher sensitivity 
for osseous metastatic disease than 18F-FDG (100% vs 72%), but that only a negative 18F-FDG 
PET/CT was predictive of overall survival, suggesting that 18F-FDG activity is more closely linked 
to biologically active metastatic disease.  This study supports the idea that skeletal 18F-FDG 
uptake principally occurs in breast cancer cells while skeletal 18F-NaF uptake is reflective of 
bone remodeling and associated blood flow (32). 
 
Targeted treatments are administered for estrogen receptor (ER) positive and human epidermal 
growth factor receptor 2 (HER2) positive tumors.  Although biopsies provide receptor 
expression information, breast cancers are heterogeneous, and biopsy may not always 
demonstrate the presence of a receptor that is present.  Further, breast cancer receptor 
expression can change over time and in response to treatment, both in the primary tumor and 
in metastases.  Hormone receptor and HER2 targeted radiotracers (33-37) are being 
investigated and may eventually allow for non-invasive dynamic, optimized therapy throughout 
breast cancer treatment.  In addition, novel radiotracers targeting hypoxia may be useful in 
therapeutic planning as hypoxic tumors can undergo mutations that increase resistance to 
chemotherapy and potentiate metastases (38-40).  One such tracer, 18F-Fluoromisonidazole 
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(18F-FMISO) accumulates in hypoxic cells with nitroreductase enzymes and has been shown to 
predict clinical resistance to anti-hormone therapy (41). 
 
Protocol 
As for a routine PET/CT exam, the patient is given a radiotracer (typically 555MBq 18F-FDG) 
intravenous (IV) injection after fasting for at least four hours.  The patient then rests for 45 
minutes in a dark room.  For a breast PET/MRI exam, a dedicated breast coil is used and the 
patient is positioned prone.  MRI sequences are then run simultaneously with the acquisition of 
PET data and IV gadolinium is administered IV after pre-contrast imaging at the normal weight-
based dose.  It is recommended that the PET data be collected for at least two minutes, 
although times from three and a half to 15 minutes have been reported (19, 42-43).  MRI 
sequences can vary, including the sequences recommended by the American College of 
Radiology (5) or can be customized, for example to include  abbreviated breast MRI sequences 
(a single pre- and post-contrast T1-weighted image set) and/or DWI, and MRS. 
 
Whole body PET/MR imaging uses the same radiotracer (typically 18F-FDG) dose, fasting time, 
and resting time.  The exam, however, is performed with supine positioning and head and body 
matrix coils.  The exam is split into stations, such as head, neck, chest, abdomen, pelvis, and 
thighs, and can be acquired either from caudal to cranial or the reverse.  These stations can 
then be combined into a single image set as part of post-processing.  PET data should be 
acquired for at least 2 minutes per station (or for the entire duration of MR imaging at each 
station) The authors scan from the thighs through the vertex, with a gadolinium injection during 
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the abdomen station to see contrast in the liver and to facilitate post-contrast evaluation of the 
brain. In breast cancer patients, dynamic contrast-enhanced (DCE) MRI has been shown to best 
detect breast and brain lesions, DWI has outperformed DCE MRI for liver and bone metastases, 
and PET has had high sensitivity for lymph node metastases (44).  Suggested sequences are 
listed in Table 1. 
INDEX LESION EVALUATION 
Benign vs. Malignant 
DCE breast MRI has a high sensitivity, reported at up to 100% (3,4) and a positive predictive 
value above 35% (45). PET/CT is not routinely performed for breast cancer detection because is 
it not adequately sensitive (46-50), especially for lobular cancers (48) and for cancers less than 
1cm (50).  Authors have investigated whether combining DCE MRI and PET data in the breast 
can improve the diagnostic accuracy for breast cancer (6, 7, 11) but have found that the 
addition of PET often decreases the sensitivity of DCE-MRI.   
In a study of 101 benign and malignant breast lesions, Botsikas et al compared DCE MRI with 
qualitative and quantitative 18F-FDG PET/MRI and reported areas under the curve (AUC) of 
0.9558, 0.8347, and 0.8855 with MRI, qualitative, and quantitative 18F-FDG PET/MRI (6).  
Although the specificity of DCE MRI improved from 67% to 100%, the authors did not 
recommend adding PET to MRI because of the compromised sensitivity (6).  Similarly, adding 
PET to DCE MRI data decreased sensitivity from 93% to 88% in a study of 58 breast lesions by 
Heusner et al (7).   
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However, Bitencourt et al showed that when multiple MR parameters are included in a PET/MR 
evaluation, 100% sensitivity could be achieved (46).  In this study, the authors evaluated 38 
lesions, 29 of which were malignant, with DCE MRI, DWI, and 18F-FDG PET.  A lesion had to 
meet one of three criteria: a washout curve on DCE MRI,  ADCmin <1.00 × 10 mm/s, or 
18F-FDG 
uptake above background.  The specificity in this study was 55% (46).  In another multi-
parametric study, Pinker et al included four parameters- PET DCE MRI, DWI and 1hydrogen-
MRS, in their evaluation of 78 indeterminate or suspicious breast lesions (51).  While the 
authors demonstrated that combining all 4 parameters would have reduced unnecessary 
biopsies by 50% as compared with DCE MRI alone, this extensive exam may not be clinically 
practical. Figure 1 shows an example of multi-parametric imaging of a triple negative breast 
cancer.  In an investigation of advanced perfusion, Jena et al. performed a feasibility study, 
looking at whether the pharmacokinetic DCE-MRI parameters Ktrans (a volume transfer 
coefficient reflecting vascular permeability), Kep (a flux rate constant), and Ve (an extracellular 
volume ratio) from a high resolution breast MRI protocol on an integrated [18F]FDG PET/MRI 
system could separate benign and malignant lesions as well as those same metrics obtained 
from a stand-alone 3T scanner (52). The authors showed sensitivities of 98.6%, 82.9%, and 
98.6% for Ktrans, Kep, and ve for detecting breast cancers, and accuracies of 94.50%, 79.82% and 
87.16% for these same variables (52).  These results are improved over their earlier work on a 
stand-alone 3T MRI (53), suggesting advanced DCE MRI metrics obtained on an integrated 
scanner are valid.  
Relationships between PET/MR metrics and clinical features 
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Advanced MRI can provide several perfusion and diffusion metrics which have been looked at, 
together with PET metrics, in efforts to predict clinical features through imaging analyses.   
Although some authors have seen correlations between PET and MR metrics, as described 
below, these correlations are not uniform between studies. 
Metastatic disease, Ki67 
 Margolis et al. evaluated perfusion data Ktrans, Kep, and Ve, and 
18F-FDG PET data standardized 
uptake value (SUV) and metabolic tumor volume (MTV) in breast cancer patients with and 
without metastases (54). In this study, Ktrans and SUVmax correlated positively with metastatic 
disease whereas kep correlated negatively.  Similarly, tumors with higher levels of Ki67, a 
marker for cell proliferation, showed a significantly greater Ktrans compared to tumors with 
lower levels of Ki67 (54). Data like these suggest the potential for Ktrans and SUVmax to suggest 
patients in whom whole body imaging should be performed to assess for metastatic disease. 
Tumor markers 
 Catalano et al investigated whether 18F-FDG PET/MR could differentiate between histological 
phenotypes of breast cancer in 21 patients with invasive ductal carcinoma (IDC) (55).  The 
authors found that estrogen receptor (ER) and progesterone receptor (PR) negative tumors had 
higher SUVmax and kep than ER or PR positive tumors; that HER2 negative tumors had higher 
apparent diffusion coeffieient (ADC)mean,  kep, and SUVmax values; and that tumors with lower 
levels of Ki67 showed lower ADCmean, but not greater ktrans, as seen in the Margolis study (54).  
PET/MR markers correlated with immunohistochemical (IHC) phenotype in 62%, a promising 
beginning (55). 
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Survival 
An et al. looked at 67 women with breast cancer with DCE MRI and 18F-FDG PET performed 
separately and demonstrated an inverse relationship between SUVmax and Ve and, notably, a 
negative correlation between metabolic heterogeneity and survival (56).  These same authors 
also found a positive correlation between SUVmax and Kep in non-triple negative breast cancers 
(TNBC), but not in TNBC (57).   
SUVmax and ADC 
 High SUVmax is a marker for tumors with high concentrations of glucose uptake and has been 
positively correlated with many clinical factors including tumor grade (58-61), stage (58), size 
(58-61), ER negativity (58-62), PR negativity (58, 62), HER2 positivity (58, 59), TNBC (50, 61), 
higher Ki67 (50, 58, 62), and axillary lymph node positivity (58-61).  SUVmax has also been 
correlated inversely with both progression free survival and overall survival (60).  High levels of 
restricted diffusion are a marker for malignancy and generate low ADC values.  Correlations 
between ADC values and clinical factors appear less replicable than those between SUVs and 
clinical markers. For example, ADC has been inversely correlated with ER positivity (61), HER2 
negativity (60, 61), tumor size, Ki67 expression, histologic subtype, the presence of axillary 
metastases and TNM staging (58).  However, in a study by Karan et al. of 70 women with breast 
cancer, no correlations between ADC median and many of these metrics (size, grade, lymph 
node status, ER status, HER2 status) were seen (59). Several authors have investigated whether 
SUVmax and ADC are inversely related and have obtained mixed results (50, 58-61), suggesting 
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that these markers reflect two separate and not necessarily related properties of breast 
cancers. 
LOCO-REGIONAL STAGING 
Loco-regional staging of breast cancer includes primary tumor size, assessment of multi-
focality, and detection of nodal disease in the axillae and internal mammary (IM) chains. 
Accurate loco-regional staging is important for surgical and oncologic planning as well as post-
treatment surveillance. 
 
Tumor Size and Multi-focality 
While PET/MRI appears to outperform PET/CT, PET/MRI does not appear to offer benefit over 
the current standard, MRI alone, in assessing tumor size or multi-focality, the presence of at 
least one additional malignant focus less than 5 cm from the index lesion.  Multifocality is 
associated with an increased likelihood of nodal disease (64) and may be associated with an 
increased risk of recurrence after lumpectomy (65). A study by Grueneisen et al. of PET/MRI 
versus PET/CT and MRI alone in 49 patients with 50 breast cancers demonstrated that PET/MRI 
and MRI alone correctly identified the T-stage of breast cancers a significantly higher number of 
times than PET/CT [41/50 (82%) PET/MRI and MRI alone vs 34/50 (68%) PET/CT; p < 0.05] (8). In 
the same study by Grueneisen et al., PET/MRI and MRI alone correctly identified 
multifocal/multicentric disease in 8/9 patients, compared with 5/9 by PET/CT.  Similar to 
Grueneisen et al., Goorts et al. found that PET/MRI and MRI alone were equivalent for 
assessing breast tumor size and multifocality in 40 patients with breast cancer (66). 
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Two additional studies demonstrated MRI to be more sensitive than PET/CT for the detection of 
multifocal breast cancer, while PET/CT demonstrated higher specificity. Jung et al. compared 
the two modalities among 105 biopsy-proven breast cancers. MRI detected all 105 primary 
tumors, while PET/CT identified 85/105 (81.0%) primary tumors. Additional foci of malignancy 
were present in the same breast in 25 cases at surgical pathology. The authors reported that 
the sensitivity of MRI for detecting these ipsilateral lesions was significantly higher than PET/CT 
(p < 0.001), while the specificity of PET/CT was superior to that of MRI (p < 0.008) (48). A similar 
study by Ergul et al. reported that in 24 patients with early-stage breast cancer, the sensitivity 
and specificity of PET/CT and MRI for the detection of multifocality were 67% versus 78% and 
100% versus 53%, respectively (9).  Finally, in comparing PET imaging alone versus MRI alone, 
Taneja et al. identified multifocal/multicentric disease in 21/36 patients. MRI detected a 
significantly higher number of satellite lesions compared with PET (35 versus 17, p = 0.001); 
however, 4 MRI-detected satellite lesions proved to be false positives at pathology (43).  
  
Axillary and Internal Mammary Lymph Nodes 
In contrast to tumor size and extent, most, but not all, studies indicate that PET-based imaging 
is more sensitive than MRI for the detection of axillary metastases and limited studies show PET 
and MRI have similar sensitivity for internal mammary nodes. In Grueneisen et al.’s cohort of 49 
patients, 18 patients had axillary disease. The sensitivity for axillary nodal status was 78% for 
PET/CT, 78% for PET/MRI, and 67% for MRI alone; these differences were not statistically 
significant, likely due to the relatively small number of patients. PET/CT also demonstrated a 
slightly superior specificity of 94% for axillary disease, compared with 90% for PET/MRI and 87% 
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for MRI alone (8). Among the 24 patients in Ergul et al.’s series, 15 patients had axillary 
involvement diagnosed by axillary lymph node dissection. The sensitivity of PET/CT for axillary 
metastasis was 67%, compared with 47% for MRI. The specificity of PET/CT for axillary nodal 
disease was also higher than MRI, 89% versus 78%, respectively (9). Notably, the CT portion of 
PET/CT appears critical to the sensitivity of staging the axilla using PET: without CT, the 
sensitivity of PET alone for the presence of axillary metastasis has been reported at 60% by 
Taneja et al. compared with 93.3 % for MRI alone. The specificity of both PET alone and MRI 
alone for axillary metastases was 91% in this study (43).  Botsikas et al. evaluated the 
performance of PET/MRI versus MRI alone for the detection of axillary, IM, and supraclavicular 
lymph nodes, and reported combined results in 58 patients with breast cancer.  Contrary to the 
studies described previously, MRI alone demonstrated increased sensitivity of 88% versus 79% 
for PET/MRI, although this difference was not statistically significant. Specificity was also not 
significantly different, reported as 98% for MRI and 100% for PET/MRI (6). 
 
Regarding changing axillary nodal status, Goorts et al. reported 1 case of axillary down-staging 
and 1 case of axillary up-staging by PET/MRI compared with conventional imaging (66). One 
study evaluated the impact of dedicated axillary PET/MRI on axillary nodal status in 12 patients 
with clinically positive axillary nodal disease. In this study, axillary PET/MRI changed nodal 
status in 40% of patients compared with ultrasound, in 40% of patients compared with 
contrast-enhanced MRI, and in 22% of patients compared with PET/CT (67).    
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In addition to staging the axilla, cross-sectional imaging affords evaluation of the IM chains. The 
identification of IM adenopathy is important as this finding is associated with a poorer 
prognosis and may warrant more aggressive treatment (68, 69). While MRI is increasingly 
performed to assess the extent of disease following a new diagnosis of breast cancer (70), few 
studies have evaluated the performance of MRI for the detection of IM metastasis, let alone 
compared MRI with PET-based imaging in this context. In 1999, Kinoshita et al. reported a 
sensitivity of 93.3% and a specificity of 89.3% among 43 MRI-detected IM nodes in 16 patients 
(71). In the above-mentioned study of 40 patients by Goorts et al., PET/MRI detected 1 
abnormal IM node not initially seen on MRI alone and increased diagnostic confidence in 3 
other cases of IM metastases (66). Jochelson et al. compared the prevalence of IM adenopathy 
identified by MRI with that by PET/CT. MRI detected IM disease in 14/90 (16%) patients, versus 
13/90 (14%) patients by PET/CT (p = 0.317) (69). The similar performance between PET/CT and 
MRI for IM nodes and the superiority of PET/CT over MRI for axillary nodes suggest a role for 
PET in the complete loco-regional staging of breast cancer. 
  
NEO-ADJUVANT THERAPY 
Predicting breast cancer response to chemotherapy is a field of particular interest for PET/MRI.  
With the emerging field of radiomics, large volumes of quantitative features can be pulled from 
both PET and MR images and converted into data (72).   These data can be mined and shared 
and, over time, may lead to discovery of certain PET/MR radiomic signatures that can help 
determine optimal therapies for individual breast cancers, such as which drugs will be most 
effective and whether to begin treatment with chemotherapy or surgery. .  Such signatures can 
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be automatically derived from images, as demonstrated by Drukker et al, who, in a study of 143 
women who underwent breast cancer treatment, showed that a near completely automatically 
extracted data point called most enhancing tumor volume (METV) predicted recurrence with 
similar accuracy to a semi-manual method published by Hylton et al (73, 74).  Below are 
examples of investigations into the clinical relevance of several PET- and MRI- based metrics 
that could eventually contribute to radiomics. 
Response prediction 
Cho et al performed 18F-FDG PET/MRI in 26 breast cancer patients before and after the first 
round of chemotherapy and evaluated qualitative MRI parameters as well as quantitative PET 
and MRI parameters (75).  While the qualitative MRI parameters were not found to be different 
between pathologic complete responders and pathologic non-complete responders, reductions 
in total lesion glycolysis (TLG) and signal enhancement ratio (SER) were different between the 
two groups.  Separately, the specificity (for pathologic complete response) of TLG30% was 100% 
and of SER was 71.4% and the sensitivity for predicting pathologic non complete response was 
63.2% and 84.2%, respectively.  Highlighting the synergistic potential or PET and MRI, the 
combined sensitivity was 100% and specificity was 71.4%. 
Wang et al also investigated the synergy between PET and MRI parameters in predicting 
response to chemotherapy (76).  In their study of 14 women with breast cancer, women 
underwent scanning before and after the first or second cycle of treatment.  They found that % 
change in SUVmax,TLG, and peak enhancement ratio (PER) predicted response (AUC 0.898, 
0.878, and 0.837) and that combined PET and MRI metrics % change SUVmax/% change ADCmin 
and % change TLG/% change ADCmin had even higher AUC for differentiating pathologic 
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complete responders from pathologic non-complete responders (AUC 0.976 and 0.905) (77).   
In a study of 93 breast cancer patients, Pengel et al. demonstrated that combined PET/MR 
metrics in concert with clinical data yielded the best accuracy (77). While age, breast cancer 
subtype, % change in SUVmax and % change in largest tumor diameter on MRI predicted near 
pCR, breast cancer subtype together with changes in SUVmax and tumor diameter provided the 
highest AUC (0.90) (78).  An et al. also showed that combining data, in this case, DWI or DCE-
MRI with PET, led improvement, here in NPV and specificity (78). An example of pre- and post-
chemotherapy imaging is shown in Figure 2. 
Lim et al. looked at changes in PET and MR metrics in response to therapy to predict disease 
free survival found that patients who met cutoffs for (lesser) declines in both SUV and MR slope 
had a higher recurrence rate (78%) than those that did not (13%) (79).  Additional studies have 
shown that both PET and MRI metrics change in response to chemotherapy in pathologic 
responders (62, 80), and that changes in SUVmax may be more accurate than changes in tumor 
size, but none of these metrics predicts with 100% accuracy.  
Highlighting the potential for advanced integrated PET/MR, advanced MR techniques including 
Sodium (23Na) MR and 1H-MRSI have also been investigated together with PET.  Jacobs et al 
investigated changes in sodium concentrations with 23Na MR in 6 patients before and after 
initial rounds of treatment and compared with 18F-FDG PET/CT and DCE MRI (81).  Tissue 
sodium concentrations increased in all partial responders and decreased in the single non-
responder, whereas MRI tumor volumes and SUVmax decreased in both partial responders and 
in non-responders.  Cho et al. (82) compared 1H-MRSI with PET.  The authors found mean % 
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reductions for total choline, SUVmax, SUVpeak, and TLG were greater in the pCR group than in 




In patients with breast cancer who require whole-body imaging prior to definitive treatment or 
for follow-up after therapy, PET/MRI is a versatile imaging tool that can provide whole-body 
staging during a single exam; suggested imaging sequences are listed in Table 1. (Figure 3).  
Although who requires whole body PET-based imaging is not standardized, a study of untreated 
breast cancer patients by Groheux et al showed that PET/CT detects unsuspected metastatic 
disease in  2.3% of clinical stage IIA patients, who are predominantly patients with tumors 
between 2cm and 5cm and, less commonly, patients with tumors less than 2cm but with 
axillary nodal disease, and that this percentage increases steadily up to 47.1% of clinical stage 
IIIC patients, who are patients with any tumor size who have involvement of an internal 
mammary node, a supra-clavicular node, or at least 10 axillary nodes (83) .  In addition, PET/CT 
is used to assess for metastatic disease in treated breast cancer patients who present with new 
symptoms or with rising tumor markers.  In terms of PET-based imaging, multiple studies have 
demonstrated improved sensitivity of whole-body PET/MRI over whole-body PET/CT in the 
context of breast cancer and other cancers (Table 2), including for detection of liver and bone 
metastases – the two most common sites of distant breast cancer spread (84). In a study of 242 
breast cancer metastases in 51 patients, PET/MRI demonstrated significantly improved 
detection of 40 liver metastases compared with PET/CT (p < 0.001), and significantly improved 
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detection of 107 bone metastases compared with PET/CT (p = 0.012); brain metastases were 
also identified by PET/MRI in 5 patients (44). Similar findings of improved detection of osseous 
breast cancer metastases with PET/MRI versus PET/CT were described in a series of 65 bone 
metastases in 17 patients with recurrent breast cancer by Sawicki et al. (85). In a study by 
Catalano et al., PET/MRI identified significantly more breast cancer metastases to bone 
compared with PET/CT (141 vs 90, p < 0.001) in 25 patients (86). Catalano et al. also reported 
significantly improved whole-body staging in 51 patients with invasive breast cancer using 
PET/MRI versus PET/CT (50/51 vs 38/51 correct, p < 0.01) (87). 
Regarding pulmonary metastases, in the same study of 242 breast cancer metastases 
mentioned above, PET/CT showed a trend towards improved detection of 23 lung metastases 
compared with PET/MRI (p = 0.065) (44). However, the clinical importance of lung lesions 
missed by PET/MRI is unclear. In a study of 208 patients with various primary malignancies 
(including 15 with breast cancer), 97% of lung nodules < 1 cm not identified on PET/MRI were 
stable or resolved on follow-up; in a single patient, three such lung nodules not seen by 
PET/MRI did progress (88). 
Finally, especially when looking for recurrences, it should be noted that while PET/MRI is 
sensitive for lesions throughout the body dedicated breast MRI or prone breast PET/MRI is 
superior to supine whole-body PET/MRI, for breast lesions, likely due to tissue collapse in the 
supine position. In a study by Kong et al., only 4/10 (40%) sub-centimeter breast cancers were 
seen on whole-body PET/MRI (49). In a study by Sasaki et al., primary breast cancers were seen 
in all 94 patients on dedicated prone breast/MRI, while whole-body PET-MRI did not identify 
primary breast cancers in 7/94 (7%) patients (89).  Therefore, in patients with elevated tumor 
This article is protected by copyright. All rights reserved.
markers and negative whole body imaging, consideration may be given to dedicated breast 
imaging.  A comparison of PET/MRI with MRI and PET/CT for clinical tasks is provided in Table 3.  
CLINICAL RELEVANCE 
PET/MR is a promising flexible imaging tool that may be of use in dedicated breast exams and in 
whole body exams.   When used with multiple MRI parameters, breast PET/MRI has shown 
promise in reducing unnecessary biopsies that would be recommended based on ther current 
standard DCE-MRI (50).  However, the radiation dose and imaging, processing, and reading 
times associated with such an exam make it unlikely this type of breast imaging will become 
part of our clinical routine.  Instead, breast PET/MR may be more important before and during 
neo-adjuvant therapy, where multiple layers of imaging parameters may eventually be 
converted into radiomic data that may lend increased precision to breast cancer treatments; 
and in local staging, where the improved evaluation of the axilla potentially afforded by 
PET/MRI may eventually preclude the need axillary lymph node tissue sampling (6, 66).  For 
breast cancer patients in need of whole body staging or post-treatment surveillance, PET/MR 
outperforms PET/CT at a much lower radiation dose (44).  Here, the inclusion of DWI in 
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Table 1. Whole-body PET/MRI in patients with breast cancer: Suggested MRI 
sequences by imaging station    
 
Station  T1-weighted sequences  T2-weighted sequences  
 Notes     
All   Coronal 3D gradient-echo  Coronal high-speed turbo-spin 
echo T2 For DIXON-based µ-map 
 
Bone/Pelvis  Radial non-contrast 3D  Axial high-speed turbo-spin echo 
 Non-contrast T1 for fat- 
gradient-echo, or T1 Dixon  or Axial 3 b-value DWI  
 containing lesions 
 
Liver/Abdomen Radial 3D fat-suppressed  Axial high-speed turbo-spin echo, 
 Fat-saturated T2 for fat- 
   gradient-echo, with or without Axial 3 b-value DWI, Axial fat- 
 containing lesions 
   contrast*    saturated T2 
 
Lung/Thorax  Radial 3D fat-suppressed 
   gradient-echo with or without 
   contrast  
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Brain/Head  Post-contrast magnetization T2 post-contrast FLAIR  
 Pre-contrast for  
   prepared rapid gradient-echo, or      
 hemorrhage† 
   pre-contrast 3D gradient-echo†      









             
      
* Contrast injection at the liver station facilitates non-contrast evaluation of the pelvic 
bones, contrast-enhanced assessment of the liver, and delayed post-contrast 
visualization of the brain. 
† Pre-contrast evaluation of the brain is only possible if contrast was not injected at the 
liver station.
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Table 2. Whole-body PET/MRI versus PET/CT for the detection of organ-specific metastases     
Study*  Primary       Metastatic Site* 
   Cancer 
     Liver   Bone   Lung   Pleura  Lymph nodes  
Beiderwellen93 Various    n=48; 48, 45 
 
Drzezga22  Various n=11; 9, 11  n=14; 14, 14  n=15; 15, 15    n=27; 27, 27 
 
Eiber94  Various    n=90; 86, 86 
 
Heusch23  Various            n=13; 13, 11 
 
Huellner24  Various       n=17; 17, 17    n=74; 74, 74 
 
Jeong95  Various n=1; 1, 1  n=11; 11, 11 
 
Melsaether44† Breast  n=40; 36, 29  n=107; 103.5, 98 n=23; 18.5, 22.5  n=16; 16, 16  n=60; 57, 54 
 
Pace19  Breast     n=11; 11, 11  n=3; 3, 3    n=35; 35, 35 
 
Schäfer96  Pediatric n=5; 5, 5  n=4; 4, 4       n=28; 28, 28 
                    
* For each study, the number of metastases to a particular organ is indicated (if evaluated), followed after the semicolon by the 
number of metastases identified by PET/MRI and PET/CT, respectively. 
† This study by Melsaether et al. included two PET/MRI readers and two PET/CT readers. The number of lesions identified by 
PET/MRI and PET/CT in this table indicates the average of the two readers for each modality. 
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Table 3. Imaging evaluation of extent of disease in breast cancer: A review of the literature comparing imaging modalities      
 
Author   T-stage/  Multifocality  Axillary Nodes  Internal Mammary Distant Metastases  
  PET Station  Tumor size        Nodes       
Grueneisen
8
  PET/MRI > PET/CT
‡
 PET/MRI > PET/CT* PET/MRI = PET/CT* 
  Whole body PET/CT       PET/CT > PET/MRI
†
 
  Breast PET/MRI PET/MRI = MRI  PET/MRI = MRI* PET/MRI > MRI* 





  MRI > PET/CT*  PET/CT > MRI* 






  PET/MRI = MRI  PET/MRI = MRI*    PET/MRI > MRI* 




      MRI > PET/CT*
‡ 
MRI > PET/CT* 








      MRI > PET/CT*  PET/CT > MRI
*
 







     MRI > PET*
‡
  MRI > PET*
‡
     MRI > PET*
‡
 







        PET/MRI > US 
  Whole body (PET/CT)       PET/MRI > MRI 




           MRI > PET/CT* 




              PET/MRI > PET/CT*
‡
 




              PET/MRI > PET/CT* 




              PET/MRI > PET/CT*
‡
 





              PET/CT > DWI* 
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  Whole body              PET/CT > DWI
†‡
 
                    
* Sensitivity and 
† 
Specificity indicated where applicable. 
‡
 Denotes statistical significance. Note that statistical significance was not demonstrated in several of these studies with small sample sizes. 
Absolute comparisons between modalities are reported in this table for reference and do not imply statistical significance unless indicated.
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Figure 1. A 38 year old female diagnosed with triple negative invasive ductal carcinoma of the 
left breast. At the time of the examination, there was no evidence of metastatic disease. (a) The 
top row is the PET, the middle row is the DCE-MRI, and the bottom row is the fused PET/MRI 
images. The index lesion is well characterized on these images as a FDG-avid heterogeneously 
enhancing lesion in the left breast abutting the skin surface. (b) A diffusion weighted image 
demonstrates increased signal intensity within the mass. (c) The corresponding ADC map 
demonstrates decreased signal intensity within the mass consistent with diffusion restriction.  
Figure 2. A 37 year old female with left breast invasive ductal carcinoma and no evidence of 
distant metastatic disease. The patient proceeded to complete a course of neo-adjuvant 
chemotherapy. PET/MRI was performed at time of diagnosis and then following completion of 
chemotherapy. (a) Pre-neoadjuvant PET/MRI. The top row is the PET, the middle row is the 
DCE-MRI, and the bottom row is the fused PET/MRI images. The index lesion is well 
characterized on these images as a FDG-avid heterogeneously enhancing lesion in the left 
breast. (b) A diffusion weighted image demonstrates increased signal intensity within the mass. 
(c) The corresponding ADC map demonstrates decreased signal intensity within the mass 
consistent with diffusion restriction. (d) Post-neoadjuvant PET/MRI. The top row is the PET, the 
middle row is the DCE-MRI, and the bottom row is the fused PET/MRI images. Following 
chemotherapy, there is mild increased signal around the biopsy clip on MRI (white arrow), but 
no FDG activity on PET and no abnormal signal on DWI or the ADC map (e and f), consistent 
with the complete pathological response confirmed at excision.  
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Figure 3a. A 62 year old female with a left breast invasive ductal carcinoma with positive left 
axillary lymph nodes. Whole-body PET/MR detected distant metastatic disease in this patient 
which was not previously diagnosed. (a) The top row is the PET, the middle row is the DCE-MRI, 
and the bottom row is the fused PET/MRI images. The index lesion is well characterized on 
these images as a FDG-avid avidly enhancing mass in the left breast. An unexpected rib 
metastasis is seen enhacing on DCE MRI and is FDG avid on PET (arrow).  
Figure 3b.  Whole body PET/MR a. T1-weighted contrast enhanced MRI and b. fused PET/MRI 
demonstrate an enlarged FDG avid axillary lymph node and an FDG avid mediastinal lymph 
node. The mediastinal lymph node is best seen on PET. In the pelvis, an iliac metastasis is better 
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